Bluebird Bio Inc. (BLUE) Trading Up 1.8%
Bluebird Bio Inc. (NASDAQ:BLUE)’s share price was up 1.8% during mid-day trading on Wednesday . The company traded as high as $57.00 and last traded at $55.89, with a volume of 706,223 shares trading hands. The stock had previously closed at $54.91.
A number of equities analysts have issued reports on BLUE shares. Zacks Investment Research downgraded Bluebird Bio from a “hold” rating to a “sell” rating in a research note on Monday, May 2nd. Wedbush reaffirmed an “outperform” rating and issued a $117.00 price target on shares of Bluebird Bio in a report on Thursday, May 5th. Wells Fargo & Co. reaffirmed a “buy” rating on shares of Bluebird Bio in a report on Thursday, May 5th. BTIG Research reaffirmed a “buy” rating and issued a $72.00 price target on shares of Bluebird Bio in a report on Saturday, May 7th. Finally, Jefferies Group reissued a “buy” rating and set a $80.00 target price (down previously from $84.00) on shares of Bluebird Bio in a report on Saturday, May 7th. Six equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. Bluebird Bio presently has a consensus rating of “Buy” and a consensus price target of $82.50.
The company’s 50-day moving average is $52.34 and its 200 day moving average is $46.94. The stock’s market capitalization is $1.86 billion.
Bluebird Bio (NASDAQ:BLUE) last announced its quarterly earnings results on Wednesday, August 3rd. The company reported ($1.59) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.44) by $0.15. The business had revenue of $1.55 million for the quarter, compared to the consensus estimate of $2.01 million. During the same quarter in the prior year, the company posted ($1.57) EPS. The business’s revenue was down 68.6% compared to the same quarter last year. On average, analysts predict that Bluebird Bio Inc. will post ($6.14) EPS for the current year.
In other Bluebird Bio news, insider Eric Sullivan sold 2,912 shares of Bluebird Bio stock in a transaction on Wednesday, July 27th. The shares were sold at an average price of $55.01, for a total value of $160,189.12. Following the sale, the insider now directly owns 4,456 shares in the company, valued at approximately $245,124.56. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider David Davidson sold 1,000 shares of Bluebird Bio stock in a transaction on Wednesday, June 15th. The shares were sold at an average price of $40.11, for a total transaction of $40,110.00. Following the completion of the sale, the insider now owns 10,600 shares in the company, valued at $425,166. The disclosure for this sale can be found here.
Other institutional investors have modified their holdings of the company. Dimensional Fund Advisors LP boosted its position in shares of Bluebird Bio by 6.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 74,831 shares of the company’s stock worth $4,806,000 after buying an additional 4,454 shares during the last quarter. State of Tennessee Treasury Department boosted its position in shares of Bluebird Bio by 45.4% in the fourth quarter. State of Tennessee Treasury Department now owns 191,963 shares of the company’s stock worth $12,328,000 after buying an additional 59,952 shares during the last quarter. RS Investment Management Co. LLC boosted its position in shares of Bluebird Bio by 91.6% in the fourth quarter. RS Investment Management Co. LLC now owns 515,846 shares of the company’s stock worth $33,128,000 after buying an additional 246,622 shares during the last quarter. Finally, Jennison Associates LLC boosted its position in shares of Bluebird Bio by 171.3% in the fourth quarter. Jennison Associates LLC now owns 864,314 shares of the company’s stock worth $55,506,000 after buying an additional 545,727 shares during the last quarter.
bluebird bio, Inc is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.